Hepion Pharmaceuticals (Hepion Pharmaceuticals) Float Percentage Of Total Shares Outstanding : 99.95% (As of Jun. 10, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Hepion Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Hepion Pharmaceuticals's float shares is 5.47 Mil. Hepion Pharmaceuticals's total shares outstanding is 5.47 Mil. Hepion Pharmaceuticals's float percentage of total shares outstanding is 99.95%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Hepion Pharmaceuticals's Insider Ownership is 13.22%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Hepion Pharmaceuticals's Institutional Ownership is 5.63%.

Hepion Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Hepion Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	5.47	/	5.47
	=	99.95%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hepion Pharmaceuticals (Hepion Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hepion Pharmaceuticals Inc (NAS:HEPA) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

399 Thornall Street, First Floor, Edison, NJ, USA, 08837

Website

https://www.hepionpharma.com

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Executives

Peter Wijngaard	director	8 SYLVAN WAY, PARSIPPANY NJ 07054
Robert T Foster	officer: Chief Scientific Officer	C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Kaouthar Lbiati	director	399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Anand Reddi	director	399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
John T Cavan	officer: Chief Financial Officer	C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10022
John P Brancaccio	director	C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob	director, officer: CEO and President
Donald E Garlikov	10 percent owner	41 S. HIGH STREET, SUITE 3400, COLUMBUS OH 43215
Tamar D Howson	director
Thomas Phd Adams	director
Gabriel Cerrone	10 percent owner	VIA SANT' ANDREA 18, MILAN L6 20121
John Z Sullivan-bolyai	officer: Chief Medical Officer	C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, 1ST FLOOR, EDISON NJ 08837
James Sapirstein	director, officer: Chief Executive Officer	1517 SAN JACINTO, HOUSTON TX 77002
Arnold Lippa	director	C/O AURORA CAPITAL, LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
William Karl Hornung	officer: Chief Financial Officer	C/O CONTRAVIR PHARMACEUTICALS, INC., 420 LEXINGTON AVE., SUITE 300, NEW YORK NY 10170